同时接种抗SARS-CoV-2疫苗和流感疫苗的医护人员的安全性特征及SARS-CoV-2突破性感染:一项意大利观察性研究
2021年10月,意大利巴里综合医院942名医护人员中610人同时接种四价流感疫苗(Flucelvax Tetra®)和mRNA抗SARS-CoV-2疫苗(BNT162b2,Comirnaty®),238人仅接种抗SARS-CoV-2疫苗,94人先接种流感疫苗后接种抗SARS-CoV-2加强针。不良事件报告率为每100人76.1例,同时接种未增加不良事件率;SARS-CoV-2突破性感染发生率为41.5%(391/942),同时接种组与其他组相比突破性感染及有症状疾病发生率无显著差异。
要点
- 942名医护人员中610人同时接种流感疫苗和抗SARS-CoV-2疫苗,不良事件报告率为每100人76.1例。
- 同时接种两种疫苗未增加不良事件率,仅接种流感疫苗者不良事件率更低。
- SARS-CoV-2突破性感染发生率为41.5%(391/942),同时接种组与其他组无显著差异。
核心结论
- 数据提示同时接种四价流感疫苗和mRNA抗SARS-CoV-2疫苗既不影响上述产品的安全性,也与SARS-CoV-2突破性感染风险升高无关。
研究设计与样本
- 意大利巴里综合医院医护人员的观察性研究,942人纳入分析。
- 2021年10月同时或分别接种流感疫苗(Flucelvax Tetra®)和/或抗SARS-CoV-2疫苗(BNT162b2 mRNA COVID-19疫苗,Comirnaty®)。
- 610/942人同时接种两种疫苗,238/942人仅接种抗SARS-CoV-2疫苗,94人先接种流感疫苗后接种抗SARS-CoV-2加强针。
主要发现
- 717名医护人员报告不良事件,报告率为每100人76.1例。
- 同时接种两种疫苗与单独接种抗SARS-CoV-2疫苗相比,不良事件率未增加。
- 仅接种流感疫苗者不良事件率更低。
- SARS-CoV-2突破性感染发生率为41.5%(391/942)。
- 同时接种组与其他受试者相比,突破性感染及有症状疾病发生率无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In October/December 2021, World Health Organization and other international agencies recommended the offer of the third dose of anti-SARS-CoV-2 vaccine. In this period, the routine offer of seasonal influenza vaccination was also guaranteed and simultaneous administration of the two vaccines was encouraged. This study aims to evaluate the safety profile and to estimate the incidence of SARS-CoV-2 breakthrough infections in subjects receiving the anti-SARS-CoV-2 and influenza vaccines simultaneously. The study population was represented by healthcare workers (HCWs) of Bari Policlinico General Hospital who received the influenza (Flucelvax Tetra®) and/or anti-SARS-CoV-2 vaccination (BNT162b2 mRNA COVID-19 vaccine, Comirnaty®) either in coadministration or separately in October 2021. Reports of adverse events following immunization (AEFIs) were investigated to study the safety of both vaccines in coadministration and in separate-instance administration. Post-vaccination SARS-CoV-2 breakthrough infection was also studied. 942 HCWs accepted to join our study. 610/942 received both vaccines simultaneously. 25.26 % subjects (238/942) were only vaccinated against SARS-CoV-2, while the remaining 94 HCWs received the influenza vaccination first and subsequently received the anti-SARS-CoV2 booster dose. 717 HCWs reported AEFIs (Reporting Rate 76.1 per 100 subjects). Simultaneous administration of the two vaccines was not related with an increase of the rate of AEFIs compared to the single administration of SARS-CoV-2 vaccine, but the AEFIs' rate was lower among subjects who received only influenza vaccine. Post-vaccination SARS-CoV-2 infections were notified for 41.5 % of enrolled subjects (391/942). Incidence of breakthrough infection and symptomatic disease was not significantly different between the simultaneous administration group and other subjects. Our data suggests that simultaneous administration of a quadrivalent influenza vaccine and an mRNA anti-SARS-CoV-2 vaccine neither affected the safety of said products nor was associated with a higher risk of SARS-CoV-2 breakthrough infection.
引用
- Moscara L, Venerito V, Martinelli A, et al. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study. Vaccine. 2023. PMID: 37544827. doi:10.1016/j.vaccine.2023.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。